medigraphic.com
ISSN 1527-3172 (Digital)

2022, Número 1

<< Anterior Siguiente >>

MEDICC Review 2022; 24 (1)


Carbapenamase-producing Acinetobacter baumannii in China, Latin America and the Caribbean: A systematic review and meta-analysis

Yu, H, Ezpeleta-Lobato G, Han X, Carmona-Cartaya Y, Quiñones-Pérez D

Idioma: Ingles.
Referencias bibliográficas: 76
Paginas: 59-69
Archivo PDF: 410.34 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Wareth G, Brandt C, Sprague LD, NeubauerH, Pletz MW. Spatio-temporal distribution ofAcinetobacter baumannii in Germany—a comprehensivesystematic review of studies on resistancedevelopment in humans (2000–2018).Microorganisms [Internet]. 2020 Mar 6 [cited 2021 Jun 25]8(3):375. Available at: https://www.mdpi.com/2076-2607/8/3/375

  2. Viehman JA, Nguyen MH, Doi Y. Treatmentoptions for carbapenem-resistant and extensivelydrug-resistant Acinetobacter baumannii infections.Drugs [Internet]. 2014 Aug 5 [cited 2021Jun 25];74(12):1315–33. Available at: https://doi.org/10.1007/s40265-014-0267-8

  3. Pan American Health Organization [Internet].Washington, D.C.: Pan American Health Organization;c2021. Documents. Magnitud y tendenciasde la resistencia a los antimicrobianos en Latinoamérica.RELAVRA 2014, 2015, 2016. Informeresumido Organización Panamericana de Salud;2020 Oct 16 [cited 2021 Jun 25]. Available at:https://www.paho.org/es/documentos/magnitud-tendencias-resistencia-antimicrobianos-latinoamerica-relavra-2014-2015-2016. Spanish.

  4. Hu F, Guo Y, Zhu DM, Wang F, Jiang XF, Xu YC,et al. [CHINET surveillance of bacterial resistanceacross China: report of the results in 2016].Chin J Infect Chemother [Internet]. 2017 [cited2021Apr 13];17(5):481–91. Available at: http://wprim.whocc.org.cn/admin/article/articleDetail?WPRIMID=668380&articleId=668380. Chinese.

  5. World Health Organization [Internet]. Geneva:World Health Organization; c2021. Pressrelease. WHO publishes list of bacteria forwhich new antibiotics are urgently needed;2017 Feb 27 [cited 2021 Jun 3]; [about 3 p.].Available at: https://www.who.int/es/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed

  6. Jeannot K, Diancourt L, Vaux S, Thouverez M,Ribeiro A, Coignard B, et al. Molecular epidemiologyof carbapenem non-susceptible Acinetobacterbaumannii in France. PLoS One [Internet].2014 Dec 17 [cited 2021 Jun 25];9(12):e115452.Available at: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0115452

  7. Ranjbar R, Zayeri S, Mirzaie A. Development ofmultiplex PCR for rapid detection of metallo-β-lactamase genes in clinical isolates of Acinetobacterbaumannii. Iranian J Microbiol [Internet].2020 Apr [cited 2021 Jun 25];12(2):107–12.Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244819/

  8. Bartual SG, Seifert H, Hippler C, DomínguezLuzon MA, Wisplinghoff H, Rodríguez-ValeraF. Development of a multilocus sequence typingscheme for characterization of clinicalisolates of Acinetobacter baumannii. J ClinMicrobiol [Internet]. 2020 Dec 21 [cited 2021Jun 30];43(9):4382–90. Available at: https://journals.asm.org/doi/abs/10.1128/JCM.43.9.4382-4390.2005

  9. Cooke A, Smith D, Booth A. Beyond PICO: TheSPIDER tool for qualitative evidence synthesis.Qual Health Res [Internet]. 2012 Oct [cited 2021Apr 13];22(10):1435–43. Available at: https://doi.org/10.1177/1049732312452938

  10. Moher D, Liberati A, Tetzlaff J, Altman DG. Ítemsde referencia para publicar revisiones sistemáticasy metaanálisis: la Declaración PRISMA [Preferredreporting items for systematic reviews andmeta-analyses: The PRISMA Statement]. RevEsp Nutr Hum Diet [Internet]. 2014 Sep 16 [cited2020 Jun 6];18(3):172–81. Available at: https://doi.org/10.14306/renhyd.18.3.114. Spanish, English.

  11. Munn Z, Moola S, Lisy K, Riitano D, TufanaruC. Methodological guidance for systematicreviews of observational epidemiological studiesreporting prevalence and cumulative incidencedata. Int J Evid Based Healthc [Internet].2015 Sep [cited 2020 Jul 25];13(3):147–53.Available at: https://journals.lww.com/ijebh/Fulltext/2015/09000/Methodological_guidance_for_systematic_reviews_of.6.aspx

  12. Nyaga VN, Arbyn M, Aerts M. Metaprop: a Statacommand to perform meta-analysis of binomialdata. Arch Public Health [Internet]. 2014 Nov 10[cited 2020 Jul 7];72(39). Available at: https://doi.org/10.1186/2049-3258-72-39

  13. Molina Arias M. Aspectos metodológicosdel metaanálisis (1). Pediatr Atención Primaria[Internet]. 2018 Jul–Sep [cited 2020Jul 7];20(79):297–302. Available at: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1139-76322018000300020. Spanish.

  14. Hamidian M, Nigro SJ. Emergence, molecularmechanisms and global spread of carbapenem-resistant Acinetobacter baumannii. MicrobGenom [Internet]. 2019 Oct [cited 2021 May13];5(10):e000306. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861865/

  15. de Oliveira EA, de Paula GR, Mondino PJJ,Gomes Chagas TP, Bona de Mondino SS, Vieirade Mendonca-Souza CR. High rate of detectionof OXA-23-producing Acinetobacter from twogeneral hospitals in Brazil. Rev Soc BrasileiraMed Trop [Internet]; 2019 Sep 5 [cited 2021May 13];52:e20190243. Available at: https://doi.org/10.1590/0037-8682-0243-2019

  16. Zhao L, Liu SY, Li JB, Ye Y. [A multicenter studyof hospital infection with carbapenem-resistantAcinetobacter baumannii]. Chin J InfectDis [Internet]. 2018 [cited 2021 May 13];36.Available at: https://doi.org/10.3760/cma.j.issn.1000-6680.2018.04.005. Chinese.

  17. Chen F, Wang L, Wang M, Xie Y, Xia X, Li X, etal. Genetic characterization and in vitro activity ofantimicrobial combinations of multidrug-resistantAcinetobacter baumannii from a general hospitalin China. Oncol Lett [Internet]. 2018 Feb[cited 2020 Aug 20];15(2):2305–15. Availableat: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5776888/

  18. Chen Y, Ai L, Guo P, Huang H, Wu Z, Liang X,et al. Molecular characterization of multidrugresistant strains of Acinetobacter baumannii isolatedfrom pediatric intensive care unit in a Chinesetertiary hospital. BMC Infect Dis [Internet].2018 Dec 4 [cited 2020 Aug 15];15(2):2305–15.Available at: https://doi.org/10.1186/s12879-018-3511-0

  19. Chen Y, Gao J, Zhang H, Ying C. Spread of theblaOXA–23-containing Tn2008 in carbapenemresistantAcinetobacter baumannii isolatesgrouped in CC92 from China. Front Microbiol[Internet]. 2017 Feb [cited 2020 Aug 20];8:163.Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292404/

  20. Han L, Lei J, Xu J, Han S. blaOXA-23-like andblaTEM rather than blaOXA-51-like contributedto a high level of carbapenem resistance inAcinetobacter baumannii strains from a teachinghospital in Xi’an, China. Medicine (Baltimore)[Internet]. 2017 Dec [cited 2020 Aug15];96(48):e8965. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728800/

  21. Huang ZY, Li J, Shui J, Wang HC, Hu YM, ZouMX. Co-existence of blaOXA-23 and blaVIM incarbapenem-resistant Acinetobacter baumanniiisolates belonging to global complex 2 ina Chinese teaching hospital. Chinese Med J(Engl) [Internet]. 2019 May 20 [cited 2020 Aug15];132(10):1166–72. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511418/

  22. Jiang L, Liang Y, Yao W, Ai J, Wang X, ZhaoZ. Molecular epidemiology and genetic characterisationof carbapenem-resistant Acinetobacterbaumannii isolates from Guangdong Province,South China. J Glob Antimicrob Resist [Internet].2019 Jun [cited 2020 Sep 5];17:84–9. Availableat: http://www.sciencedirect.com/science/article/pii/S2213716518302182

  23. Zhao L, Liu S, Li J, Ye Y. [A multicenter study ofhospital infection with carbapenem-resistant Acinetobacterbaumannii]. Chin J Infect Dis [Internet].2018 [cited 2020 Sep 20];36. Available at:http://rs.yiigle.com/CN311365201804/1050855.htm. Chinese.

  24. Song X, Chen J, Zhai J, Zhu Y, Li C, Yang D.[A study on antibiotics resistance and carbapenemasegenotype of Acinetobacter baumannii inintensive care unit of Qingdao]. Chin J Lab Med[Internet]. 2017 [cited 2020 Sep 9];40(3):216–20. Chinese. Available at: http://rs.yiigle.com/CN114452201703/978475.htm

  25. Chen J, Xu X, Liu K, Hu X, Chen H, Chen K, etal. [NDM-1 gene and other carbapenemase genesin Acinetobacter baumannii in Jiangxi area]. ChinJ Infect Control [Internet]. 2017 [cited 2020 Aug25];2(16). Available at: https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&fi lename=GRKZ201702003&dbname=CJFDLAST2017. Chinese.

  26. Huang G, Yin S, Gong Y, Zhao X, Zou L, JiangB, et al. Multilocus sequence typing analysis ofcarbapenem-resistant Acinetobacter baumanniiin a Chinese Burns Institute. Front Microbiol[Internet]. 2016 Nov 9 [cited 2020 Aug25];7:1717. Available at: https://www.frontiersin.org/article/10.3389/fmicb.2016.01717

  27. Chen Y, Yang Y, Liu L, Qiu G, Han X, Tian S, etal. High prevalence and clonal dissemination ofOXA-72-producing Acinetobacter baumannii in a Chinese hospital: a cross sectional study. BMCInfect Dis [Internet]. 2018 Sep 29 [cited 2020 Aug20];18:491. Available at: https://doi.org/10.1186/s12879-018-3359-3

  28. Jiang M, Liu L, Ma Y, Zhang Z, Li N, Zhang F,et al. Molecular epidemiology of multi-drug resistantAcinetobacter baumannii isolated in Shandong,China. Front Microbiol [Internet] 2016Oct 21 [cited 2020 Sep 5];7:1687. Available at:https://www.frontiersin.org/articles/10.3389/fmicb.2016.01687

  29. Ning N, Liu X, Bao C, Chen S, Cui E, Zhang J,et al. Molecular epidemiology of blaOXA-23-producingcarbapenem-resistant Acinetobacterbaumannii in a single institution over a 65-monthperiod in north China. BMC Infect Dis [Internet].2017 Jan 5 [cited 2020 Sep 5];17:14. Availableat: https://doi.org/10.1186/s12879-016-2110-1

  30. Lu Q, Wei B, Li H, Zhang Y. [Drug resistanceand genotyping of β-lactamase of Acinetobacterbaumannii resistant to carbapenems in westernGuangxi]. Lab Med Clin [Internet]. 2019 [cited2020 Aug 20];16(12). Available at: https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&dbname=CJFDLAST2019&fi lename=JYYL201912011&v=M22JVof4U39XXt2EHvhofcuZ110wIxwjfwN0QqMQzLD1AewIWsfPcZClBxH6Ec18. Chinese.

  31. Zhang Y, Zhou S, Wang C. Drug resistancemechanisms and multilocus sequence typing ofcarbapenem-resistant Acinetobacter baumannii.Acta Universitatis Medicinalis Anhui[Internet].2019 [cited 2020 Sep 20];2(54). Available at:https://kns.cnki.net/kcms/detail/detail.aspx?FileName=YIKE201902032&DbName=CJFQ2019

  32. Wu H, Tan B, Zhang Z, Jiang M. [Molecularepidemiology of carbapenem-resistant Acinetobacterbaumannii isolated from a hospital]. ChinJ Exp Clin Infect Dis [Internet]. 2017 [cited 2020Sep 24];11(02). Available at: https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&dbname=CJFDLAST2017&filename=ZSGR201702012&v=%25mmd2BHO2kkKxIJBrljb3MTYg3m9hhtKs80SOGbI9s%25mmd2BM%25mmd2Fmm%25mmd2Fhjux%25mmd2Be4VPGC3PjIlGWZej.Chinese.

  33. Li P, Niu W, Li H, Lei H, Liu W, Zhao X, et al. Rapiddetection of Acinetobacter baumannii and molecularepidemiology of carbapenem-resistant A. baumanniiin two comprehensive hospitals of Beijing,China. Front Microbiol [Internet]. 2015 Sep 23[cited 2020 Sep 24];6. Available at: https://www.frontiersin.org/article/10.3389/fmicb.2015.00997

  34. Bado I, Papa-Ezdra R, Delgado-Blas JF, GaudioM, Gutiérrez C, Cordeiro NF, et al. Molecularcharacterization of crbapenem-resistantAcinetobacter baumannii in the intensive careunit of Uruguay’s University Hospital identifies the fi rst rmtC gene in the species. MicrobDrug Resist [Internet]. 2018 Sep 1 [cited 2020Aug 13];24(7):1012–9. Available at: http://dx.doi.org/10.1089/mdr.2017.0300

  35. Camargo CH, Riberio Tiba M, Saes MR, de VasconcellosFM, dos Santos LF, Caló Romero E, etal. Population structure analysis of carbapenemresistantAcinetobacter baumannii clinical isolatesfrom Brazil reveals predominance of clonalcomplexes 1, 15, and 79. Antimicrob AgentsChemother [Internet]. 2016 Apr [cited 2020 Aug13];60(4):2545–7. Available at: https://aac.asm.org/content/aac/60/4/2545.full.pdf

  36. Rocha Araújo Castilho S, Silva de MirandaGodoy C, Oliveira Guilarde A, Lamaro CardosoJ, André Porfi rio MC, Junqueira-Kipnis AP, etal. Acinetobacter baumannii strains isolatedfrom patients in intensive care units in Goiânia,Brazil: molecular and drug susceptibility profiles. PLoS One [Internet]. 2017 [cited 2020 Aug13];12(5):e0176790. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419545/

  37. Castillo Y, Nieto C, Astocondor L, Jacobs J, GarcíaC. Bacteriemia por Acinetobacter baumanniiproductor de oxacilinasa en hospitales de Lima,Perú. Rev Peru Med Exp Salud Publica [Internet].2019 [cited 2020 Aug 15];36(2):364–6. Available at:http://dx.doi.org/10.17843/rpmesp.2019.362.4152.Spanish.

  38. González-Villoria AM, Tamayo-Legorreta E,Garza-Ramos U, Barrios H, Sáchez-Pérez A,Rodríguez-Medina N, et al. A multicenter study inMexico fi nds Acinetobacter baumannii clinical isolatesbelonging to clonal complexes 636B (113B)and 92B harboring OXA-72, OXA-239, and OXA-469. Antimicrob Agents Chemother [Internet].2016 Mar 25 [cited 2020 Aug 13];60(4):2587–8.Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808170/

  39. Rodríguez CH, Nastro M, Flores SA, RodríguezM, Spinozzi M, Bruni G, et al. Epidemiologíamolecular de aislados de Acinetobacter baumanniiresistentes a carbapenems en Argentina.Rev Argent Microbiol [Internet]. 2019 Jul–Sep[cited 2020 Aug 20];51(3):247–50. Available at:http://dx.doi.org/10.1016/j.ram.2017.12.004 .Spanish.

  40. Opazo-Capurro A, San Martín I, Quezada-AguiluzM, Morales-León F, Domínguez-YévenesM, Lima CA, et al. Evolutionary dynamics ofcarbapenem-resistant Acinetobacter baumanniicirculating in Chilean hospitals. Infect GenetEvol [Internet]. 2019 [cited 2020 Sep 9];73:93–7. Available at: http://dx.doi.org/10.1016/j.meegid.2019.04.022

  41. Ovalle MV, Saavedra SY, González MN, HidalgoAM, Duarte C, Beltrán M. Resultados de la vigilancianacional de la resistencia antimicrobianade enterobacterias y bacilos Gram negativosno fermentadores en infecciones asociadas ala atención de salud, Colombia, 2012-2014.Biomédica (Bogotá) [Internet]. 2017 [cited 2020Sep 9];37:473–85. Available at: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-41572017000400473. Spanish.

  42. Quiñones D, Carvajal I, Pérez Y, Hart M, PérezJ, Garcia S, et al. High prevalence of bla OXA-23in Acinetobacter spp. and detection of bla NDM-1in A. soli in Cuba: report from National SurveillanceProgram (2010-2012). New MicrobesNew Infections [Internet]. 2015 Sep [cited2020 Sep 20];7:52–6. Available at: http://dx.doi.org/10.1016/j.nmni.2015.06.002

  43. Rodríguez CH, Balderrama Yarhui N, Nastro M,Nuñez Quezada T, Castro Cañarte G, MagneVentura R, et al. Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii inSouth America. J Med Microbiol [Internet]. 2016[cited 2020 Sep 24];65(10):1088–91. Availableat: http://dx.doi.org/10.1099/jmm.0.000328

  44. Brisolla Tavares LC, de Vasconcellos FM, deSousa WV, Rocchetti TT, Mondelli AL, FerreiraAM, et al. Emergence and persistence ofhigh-risk clones among MDR and XDR A. baumanniiat a Brazilian teaching hospital. FrontMicrobiol [Internet]. 2019 Jan 4 [cited 2020 Sep20];9:2898. Available at: https://www.frontiersin.org/article/10.3389/fmicb.2018.02898

  45. Levy-Blitchtein S, Roca I, Plasencia-Rebata S,Vicente-Taboada W, Velásquez-Pomar J, MuñozL, et al. Emergence and spread of carbapenemresistantAcinetobacter baumannii internationalclones II and III in Lima, Peru. Emerg MicrobesInfect [Internet]. 2018 Jul 4 [cited 2020 Sep5];7:119. Available at: https://doi.org/10.1038/s41426-018-0127-9

  46. Kim UJ, Kim HK, An JH, Cho SK, Park K-H, JangH-C. Update on the epidemiology, treatment, andoutcomes of carbapenem-resistant Acinetobacterinfections. Chonnam Med J [Internet]. 2014 Aug20 [cited 2020 Oct 20];50(2):37–44. Available at:https://doi.org/10.4068/cmj.2014.50.2.37

  47. Rodríguez Buenahora RD, Bustillo Zarate DE,Caicedo Sánchez DC, Cadena Sarmiento DC,Castellanos Gómez C. Acinetobacter baumannii:patógeno multirresistente emergente.MED UIS [Internet]. 2016 [cited 2020 Oct20];29(2):113–35. Available at: http://www.scielo. o r g . c o / s c i e l o . p h p ? s c r i p t = s c i _ a r t t e x t&pid=S0121-03192016000200011&nrm=iso.Spanish.

  48. Walther-Rasmussen J, Høiby N. OXA-type carbapenemases.J Antimicrob Chemother [Internet].2006 Mar [cited 2020 Oct 18];57(3):373–83.Available at: https://doi.org/10.1093/jac/dki482

  49. Nuñez Quezada T, Rodríguez CH, Castro CañarteG, Nastro M, Balderrama Yarhui N, Dabos L, etal. Outbreak of bla OXA-72-producing Acinetobacterbaumannii in South America. J Chemother[Internet]. 2017 [cited 2020 Aug 20];29(5):321–4.Available at: https://www.tandfonline.com/doi/abs/10.1080/1120009X.2016.1158936

  50. Georgescu M, Gheorghe I, Dudu A, Czobor I,Costache M, Cristea VC, et al. First report ofOXA-72 producing Acinetobacter baumannii inRomania. New Microb New Infect [Internet]. 2016Jul 21 [cited 2020 Oct 20];13:87–8. Available at:http://europepmc.org/abstract/MED/27547405

  51. Pagano M, Rocha L, Sampaio JLM, MartinsAF, Barth AL. Emergence of OXA-72-producingAcinetobacter baumannii belonging to high-riskclones (CC15 and CC79) in diff erent Brazilianstates. Infect Control Hospital Epidemiol [Internet].2017 [cited 2020 Oct 20];38(2):252–4.Available at: https://www.cambridge.org/core/product/identifier/S0899823X16002877/type/journal_article

  52. Rodrigues-Costa F, Cayô R, Pereira MatosA, Girardello R, Martins WMBS, Carrara-MarroniFE, et al. Temporal evolution of Acinetobacterbaumannii ST107 clone: conversionof blaOXA-143 into blaOXA-231 coupled withmobilization of ISAba1 upstream occAB1.Res Microbiol [Internet]. 2019 Jan–Feb [cited2021 Jun 27];170(1):53–9. Available at: https://www.sciencedirect.com/science/article/pii/S0923250818301001

  53. Girlich D, Damaceno QS, Oliveira AC, NordmannP. OXA-253, a variant of the carbapenemhydrolyzingclass D β-Lactamase OXA-143 inAcinetobacter baumannii. Antimicrob AgentsChemother [Internet]. 2014 May [cited 2021 Jun28];58(5):2976–8. Available at: https://journals.asm.org/doi/abs/10.1128/AAC.02640-13

  54. Sarikhani Z, Nazari R, Nateghi Rostami M. Firstreport of OXA-143-lactamase producing Acinetobacterbaumannii in Qom, Iran. Iranian JBasic Med Sci [Internet]. 2017 Nov [cited 2021Jun 28];20(11):1282–6. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749364/

  55. Saavedra SY, Prada-Cardozo D, Verónica R,Pérez-Cardona H, Hidalgo AM, Nilse GonzálezM, et al. Whole-genome sequence of a ColombianAcinetobacter baumannii strain, a coproducerof OXA-72 and OXA-255-like carbapenemases.Genome Announc [Internet]. 2017 Feb 16 [cited2021 Jun 28];5(7):e01558-16. Available at:https://doi.org/10.1128/genomeA.01558-16

  56. Beigverdi R, Sattari-Maraji A, Emaneini M, JabalameliF. Status of carbapenem-resistant Acinetobacterbaumannii harboring carbapenemase:fi rst systematic review and meta-analysis fromIran. Infect Genet Evol [Internet]. 2019 Sep [cited2021 Apr 13];73:433–43. Available at: https://www.sciencedirect.com/science/article/pii/S1567134819301091

  57. Alkasaby NM, El Sayed Zaki M. Molecularstudy of Acinetobacter baumannii isolates formetallo-β-lactamases and extended-spectrum-β-lactamases genes in intensive care unit,Mansoura University Hospital, Egypt. Int JMicrobiol [Internet]. 2017 [cited 2021 Apr 13];2017:3925868. Available at: https://doi.org/10.1155/2017/3925868

  58. Mesli E, Berrazeg M, Drissi M, Bekkhoucha SN,Rolain J-M. Prevalence of carbapenemaseencodinggenes including New Delhi metallo-β-lactamase in Acinetobacter species, Algeria.Int J Infect Dis [Internet]. 2013 Sep [cited 2021Apr 14];17(9):e739–e43. Available at: https://www.sciencedirect.com/science/article/pii/S1201971213001173

  59. Rodríguez CH, Nastro M, Famiglietti A. Carbapenemasesin Acinetobacter baumannii.Review of their dissemination in Latin America.Rev Argent Microbiol [Internet]. 2018 Jul–Sep[cited 2020 Oct 20];50(3):327–33. Available at:http://www.sciencedirect.com/science/article/pii/S0325754117301785

  60. Pillonetto M, Arend L, Vespero EC, Pelisson M,Chagas TPG, D’Alincourt Carvalho-Assef AP, etal. First report of NDM-1-producing Acinetobacterbaumannii sequence type 25 in Brazil. AntimicrobAgents Chemother [Internet]. 2014 Dec [cited2021 Jun 28];58(12):7592–4. Available at: https://journals.asm.org/doi/abs/10.1128/AAC.03444-14

  61. Waterman PE, McGann P, Snesrud E, Cliff ordRJ, Kwak YI, Munoz-Urbizo IP, et al. Bacterialperitonitis due to Acinetobacter baumanniisequence type 25 with plasmid-borne New Delhimetallo-β-lactamase in Honduras. AntimicrobAgents Chemother [Internet]. 2013 Sep [cited2021 Jun 28];57(9):4584–6. Available at: https://journals.asm.org/doi/abs/10.1128/AAC.00275-13

  62. Cifuentes S, Moura Q, Cardoso B, Esposito F,Cerdeira L, Álvarez E, et al. Genomic featuresof a carbapenem-resistant OXA-219-positiveAcinetobacter baumannii of international ST15(CC15) from a patient with community-onset urinarytract infection in Chilean Patagonia. J GlobAntimicrob Resist [Internet]. 2020 Sep [cited2021 Jun 28];22:756–8. Available at: https://www.sciencedirect.com/science/article/pii/S2213716520301867

  63. Bolourchi N, Azizi O, Tabrizi AMA, Esmaeili S,Fereshteh S, Badmasti F. Clonal relatedness ofAcinetobacter baumannii isolated from the MiddleEast: a systematic review. Rev Med Microbiol[Internet]. 2020 Aug [cited 2021 Jun 29].Available at: https://journals.lww.com/revmedmicrobiol/Fulltext/9000/Clonal_relatedness_of_Acinetobacter_baumannii.99747.aspx

  64. Genovese C, La Fauci V, D’Amato S, Squeri A,Anzalone C, Costa GB, et al. Molecular epidemiologyof antimicrobial resistant microorganismsin the 21th century: a review of the literature. ActaBiomed [Internet]. 2020 May 11 [cited 2021 Jun29];91(2):256–73. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569612/

  65. Grisold AJ, Luxner J, Bedenić B, Diab-ElschahawiM, Berktold M, Wechsler-Fördös A, et al.Diversity of oxacillinases and sequence typesin carbapenem-resistant Acinetobacter baumanniifrom Austria. Int J Environ Res Public Health[Internet]. 2021 [cited 2021 Jun 29];18(4):2171.Available at: https://www.mdpi.com/1660-4601/18/4/2171

  66. Gu Y, Jiang Y, Zhang W, Yu Y, He X, Tao J,et al. Risk factors and outcomes of bloodstreaminfections caused by Acinetobacterbaumannii: a case–control study. Diagnosticmicrobiology and infectious disease. DiagnMicrobiol Infect Dis [Internet]. 2021 Feb [cited2021 Jun 29];99(2):115229. Available at: https://www.sciencedirect.com/science/article/pii/S0732889320306064

  67. Jun SH, Lee DE, Hwang HR, Kim N, Kim HJ, LeeYC, et al. Clonal change of carbapenem-resistantAcinetobacter baumannii isolates in a Koreanhospital. Infect Genet Evol [Internet]. 2021 Sep[cited 2021 Jun 29];93:104935. Available at:https://www.sciencedirect.com/science/article/pii/S156713482100232X

  68. Meijie J, Li L, Liu S, Zhang Z, Li N, Zhao S.Extensively drug resistant Acinetobacter baumanniiST369 infection in emergency intensivecare unit in Shandong Province, China. ResSquare [Internet]. 2020 Jan 31 [cited 2020 Nov10]. Available at: http://europepmc.org/abstract/PPR/PPR126539

  69. López-Durán PA, Fonseca-Coronado S, Lozano-Trenado LM, Araujo-Betanzos S, Rugerio-TrujilloDA, Vaughan G, et al. Nosocomial transmissionof extensively drug resistant Acinetobacter baumanniistrains in a tertiary level hospital. PLoSOne [Internet]. 2020 Apr 17 [cited 2020 Nov10];15(4):e0231829. Available at: https://doi.org/10.1371/journal.pone.0231829

  70. Khurshid M, Rasool MH, Ashfaq UA, AslamB, Waseem M, Xu Q, et al. Dissemination ofblaOXA-23-harbouring carbapenem-resistantAcinetobacter baumannii clones in Pakistan.J Glob Antimicrob Resist [Internet]. 2020 Jun[cited 2021 Jun 30];21:357–62. Available at:https://www.sciencedirect.com/science/article/pii/S2213716520300023

  71. Khuntayaporn P, Kanathum P, Houngsaitong J,Montakantikul P, Thirapanmethee K, ChomnawangMT. Predominance of international clone 2multidrug-resistant Acinetobacter baumannii clinicalisolates in Thailand: a nationwide study. AnnClin Microbiol Antimicrob [Internet]. 2021 Mar 20[cited 2021 Jun 30];20(19). Available at: https://doi.org/10.1186/s12941-021-00424-z

  72. Shirazi AS, Shafi ei M, Solgi H, Aslani MM, AziziO, Badmasti F. Diff erent virulence capabilitiesand ompA expressions in ST2 and ST513 ofmultidrug-resistant Acinetobacter baumannii.Curr Microbiol [Internet]. 2019 Jun [cited 2021Jun 30];76(6):723–31. Available at: https://doi.org/10.1007/s00284-019-01686-9

  73. Matsui M, Suzuki M, Suzuki M, YatsuyanagiJ, Watahiki M, Hiraki Y, et al. Distribution andmolecular characterization of Acinetobacter baumanniiinternational clone II lineage in Japan.Antimicrob Agents Chemother [Internet]. 2018 Jan25 [cited 2021 Jun 30];62(2):e02190-17. Availableat: https://journals.asm.org/doi/abs/10.1128/AAC.02190-17

  74. Kostyanev T, Xavier BB, García-Castillo M, LammensC, Bravo-Ferrer Acosta J, Rodríguez-BañoJ, et al. Phenotypic and molecular characterizationsof carbapenem-resistant Acinetobacterbaumannii isolates collected within the EURECAstudy. Int J Antimicrob Agents [Internet]. 2021Jun [cited 2021 Jun 30];57(6):106345. Availableat: https://www.sciencedirect.com/science/article/pii/S092485792100087X

  75. Nawfal Dagher T, Al-Bayssari C, Chabou S,Antar N, Diene SM, Azar E, et al. Investigationof multidrug-resistant ST2 Acinetobacter baumanniiisolated from Saint George hospital inLebanon. BMC Microbiol [Internet]. 2019 Feb 2[cited 2021 Jul 2];19(1):29. Available at: https://doi.org/10.1186/s12866-019-1401-2

  76. Rezaei A, Fazeli H, Faghri J. Investigation of carbapenemresistant Acinetobacter baumannii ST2in Iran. Acta Microbiol Immunol Hung [Internet].2021 May 13 [cited 2021 Jun 29];68(1):20–6.Available at: https://akjournals.com/view/journals/030/68/1/article-p20.xml




2020     |     www.medigraphic.com